Distribution and efficacy of ofatumumab and ocrelizumab in humanized CD20 mice following subcutaneous or intravenous administration.
B-cells
distribution
intravenous
multiple sclerosis
ocrelizumab
ofatumumab
subcutaneous
Journal
Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960
Informations de publication
Date de publication:
2022
2022
Historique:
received:
12
11
2021
accepted:
27
06
2022
entrez:
15
8
2022
pubmed:
16
8
2022
medline:
17
8
2022
Statut:
epublish
Résumé
Approval of B-cell-depleting therapies signifies an important advance in the treatment of multiple sclerosis (MS). However, it is unclear whether the administration route of anti-CD20 monoclonal antibodies (mAbs) alters tissue distribution patterns and subsequent downstream effects. This study aimed to investigate the distribution and efficacy of radiolabeled ofatumumab and ocrelizumab in humanized-CD20 (huCD20) transgenic mice following subcutaneous (SC) and intravenous (IV) administration. For distribution analysis, huCD20 and wildtype mice (n = 5 per group) were imaged by single-photon emission computed tomography (SPECT)/CT 72 h after SC/IV administration of ofatumumab or SC/IV administration of ocrelizumab, radiolabeled with Indium-111 (
Identifiants
pubmed: 35967378
doi: 10.3389/fimmu.2022.814064
pmc: PMC9366925
doi:
Substances chimiques
Antibodies, Monoclonal
0
Antibodies, Monoclonal, Humanized
0
Antigens, CD20
0
ocrelizumab
A10SJL62JY
ofatumumab
M95KG522R0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
814064Informations de copyright
Copyright © 2022 Torres, Roodselaar, Sealey, Ziehn, Bigaud, Kneuer, Leppert, Weckbecker, Cornelissen and Anthony.
Déclaration de conflit d'intérêts
MZ, MB, RK, and GW report employment by Novartis. DL is a former employee of Novartis. The remaining author declares that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Neurol Neuroimmunol Neuroinflamm. 2020 Dec 16;8(1):
pubmed: 33406479
Front Immunol. 2016 Oct 17;7:430
pubmed: 27799933
Brain. 2007 Apr;130(Pt 4):1089-104
pubmed: 17438020
N Engl J Med. 2008 Feb 14;358(7):676-88
pubmed: 18272891
Semin Oncol. 2000 Dec;27(6 Suppl 12):17-24
pubmed: 11225995
Brain Pathol. 2020 Jul;30(4):779-793
pubmed: 32243032
Neurol Neuroimmunol Neuroinflamm. 2022 Feb 1;9(2):
pubmed: 35105685
J Neuroimmune Pharmacol. 2019 Dec;14(4):709-719
pubmed: 31435856
J Neurol. 2021 Apr;268(4):1210-1221
pubmed: 31363847
Ann Neurol. 2008 Mar;63(3):395-400
pubmed: 18383069
Neurol Neuroimmunol Neuroinflamm. 2021 Mar 2;8(3):
pubmed: 33653962
Ann Neurol. 1998 Apr;43(4):465-71
pubmed: 9546327
Acta Neuropathol. 2018 Apr;135(4):511-528
pubmed: 29441412
Mult Scler. 2022 Apr;28(5):683-690
pubmed: 32965168
Ann Neurol. 2010 Oct;68(4):477-93
pubmed: 20976767
Nat Med. 2008 Jun;14(6):688-93
pubmed: 18488038
Mult Scler. 2019 Dec;25(14):1915-1925
pubmed: 30566027
Neurology. 1996 Apr;46(4):907-11
pubmed: 8780061
Brain Pathol. 2004 Apr;14(2):164-74
pubmed: 15193029
Neurology. 2014 Jul 15;83(3):278-86
pubmed: 24871874
J Immunol. 2007 Sep 1;179(5):3351-61
pubmed: 17709552
Sci Transl Med. 2015 Oct 21;7(310):310ra166
pubmed: 26491076
Ann Neurol. 2018 Dec;84(6):829-842
pubmed: 30362156
Neuropsychiatr Dis Treat. 2017 Jun 26;13:1661-1667
pubmed: 28721047
Brain. 2011 Sep;134(Pt 9):2755-71
pubmed: 21840891
J Clin Invest. 2019 Jun 24;129(8):3086-3102
pubmed: 31232704
Clin Transl Sci. 2019 May;12(3):283-290
pubmed: 30737892
Croat Med J. 2019 Apr 30;60(2):87-98
pubmed: 31044580
Nat Med. 1999 Feb;5(2):170-5
pubmed: 9930864
Cell. 2018 Sep 20;175(1):85-100.e23
pubmed: 30173916
N Engl J Med. 2020 Aug 6;383(6):546-557
pubmed: 32757523
Front Immunol. 2015 Dec 24;6:636
pubmed: 26732544
J Neuroophthalmol. 2018 Jun;38(2):251-258
pubmed: 29561328
Curr Opin Neurol. 2015 Jun;28(3):193-205
pubmed: 25887774
Brain Sci. 2020 Oct 20;10(10):
pubmed: 33092190
CNS Drugs. 2016 Dec;30(12):1137-1148
pubmed: 27844213
Front Immunol. 2020 May 08;11:760
pubmed: 32457742
N Engl J Med. 2011 Dec 8;365(23):2188-97
pubmed: 22150037
Ann Neurol. 2018 Jan;83(1):13-26
pubmed: 29244240
Lancet Neurol. 2021 Jun;20(6):470-483
pubmed: 33930317
Front Immunol. 2019 Jun 20;10:1340
pubmed: 31281311
MAbs. 2013 Jan-Feb;5(1):22-33
pubmed: 23211638
Neuropharmacology. 2014 Apr;79:534-41
pubmed: 24412675
N Engl J Med. 2017 Jan 19;376(3):221-234
pubmed: 28002679
Brain. 2022 Feb 01;:
pubmed: 35104840
Front Immunol. 2019 Oct 18;10:2437
pubmed: 31681317
JAMA Neurol. 2019 Dec 1;76(12):1474-1483
pubmed: 31403674
Ann Neurol. 2015 Nov;78(5):710-21
pubmed: 26239536